First Eagle Investment Management LLC lifted its position in shares of Medtronic PLC (NYSE:MDT – Free Report) by 1.2% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 13,948,408 shares of the medical technology company’s stock after buying an additional 164,425 shares during the quarter. Medtronic comprises 1.8% of First Eagle Investment Management LLC’s holdings, making the stock its 18th biggest position. First Eagle Investment Management LLC’s holdings in Medtronic were worth $1,203,608,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of MDT. Cullen Capital Management LLC purchased a new stake in Medtronic in the 2nd quarter worth approximately $202,764,000. State Street Corp lifted its stake in shares of Medtronic by 2.7% during the 2nd quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock worth $5,005,320,000 after purchasing an additional 1,658,301 shares during the period. Amundi lifted its stake in shares of Medtronic by 36.3% during the 1st quarter. Amundi now owns 6,070,236 shares of the medical technology company’s stock worth $525,986,000 after purchasing an additional 1,616,739 shares during the period. Bank of America Corp DE boosted its holdings in shares of Medtronic by 5.4% during the first quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock worth $2,254,200,000 after purchasing an additional 1,343,220 shares during the last quarter. Finally, Flossbach Von Storch SE acquired a new stake in shares of Medtronic during the second quarter worth $85,223,000. Institutional investors and hedge funds own 82.06% of the company’s stock.
Medtronic Trading Down 0.6%
MDT stock opened at $102.24 on Wednesday. The company has a market cap of $130.78 billion, a price-to-earnings ratio of 25.18, a PEG ratio of 2.41 and a beta of 0.56. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. The business has a fifty day simple moving average of $94.09 and a 200-day simple moving average of $88.49. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33.
Medtronic (NYSE:MDT – Get Free Report) last issued its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The firm had revenue of $9.76 billion for the quarter, compared to analysts’ expectations of $9.55 billion. During the same quarter last year, the firm earned $1.26 earnings per share. The firm’s revenue for the quarter was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities research analysts expect that Medtronic PLC will post 5.98 EPS for the current year.
Medtronic Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Friday, October 16th. Stockholders of record on Friday, September 25th were issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is 70.94%.
Insider Transactions at Medtronic
In other news, EVP Michael Marinaro sold 10,420 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the completion of the sale, the executive vice president owned 105,916 shares in the company, valued at approximately $10,167,936. The trade was a 8.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of the business’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the sale, the executive vice president owned 42,186 shares of the company’s stock, valued at $3,950,718.90. The trade was a 3.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 61,903 shares of company stock worth $5,889,203 in the last three months. 0.27% of the stock is currently owned by company insiders.
Recent Medtronic Headlines
Investors following MDT have been watching these headlines:
- Positive Sentiment: The FDA cleared Medtronic’s Hugo robotic-assisted surgery system for general surgery in the U.S. The expanded authorization opens access to an estimated 3.5 million annual U.S. cases and procedures that represent more than half of U.S. soft-tissue surgeries, increasing Hugo’s commercial opportunity. Article: Medtronic’s Hugo robot gets expanded FDA clearance in general surgery
- Positive Sentiment: Medtronic plans to acquire Contego Medical for $380 million, adding carotid and peripheral vascular technologies to its portfolio. The deal builds on an existing U.S. distribution relationship and could strengthen its vascular-intervention business. Article: Medtronic to buy Contego Medical for $380M
- Neutral Sentiment: A preview of Medtronic’s Q2 results points to Cardiovascular momentum, particularly cardiac ablation, with Neuroscience and Diabetes also expected to contribute growth. These are expectations ahead of the earnings report, not reported results. Article: MDT Q2 Earnings Preview
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on MDT shares. UBS Group reaffirmed a “cautious” rating on shares of Medtronic in a research report on Wednesday, October 14th. BTIG Research reduced their target price on Medtronic from $100.00 to $99.00 and set a “buy” rating on the stock in a research report on Monday, October 12th. Needham & Company LLC reissued a “buy” rating on shares of Medtronic in a research note on Thursday, September 17th. Truist Financial restated a “hold” rating and issued a $99.00 price target (up from $86.00) on shares of Medtronic in a report on Wednesday, September 2nd. Finally, Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Monday. Nineteen research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.28.
Medtronic Company Profile
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
Featured Stories
- Five stocks we like better than Medtronic
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
